Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CC-115

Small molecule · Inhibitor of DNA-dependent protein kinase (PRKDC) and mTOR

Phase 2 Most advanced trial
1 Registered trials

What is CC-115?

CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR). It binds to and inhibits both TORC1 and TORC2 complexes, potentially reducing cellular proliferation in cancer cells. The drug is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
DNA-dependent protein kinase (PRKDC), mTOR
Mechanism
Inhibitor of DNA-dependent protein kinase (PRKDC) and mTOR
Pathways
PI3K/Akt/mTOR signaling, DNA damage response, NHEJ pathway
Therapy area
Oncology
In trials of
PBYI
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FII75TFH5L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02977780 Phase 2 Glioblastoma Recruiting PBYI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Other drugs acting on PRKDC / MTOR

Gedatolisib FDA approved Sirolimus FDA approved CERC-006 Phase 1 Encapsulated Rapamycin Phase 2 Samotolisib Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.